GEN-MKT-18-7897-A
Aug 7, 2017 | Blogs, Technology | 0 comments
Did you know you can access Knowledge Base Articles for trending user questions compiled and answered by SCIEX support experts? Doing so may help to reduce your support calls, not to mention downtime. Instead of waiting for a problem to occur, you can stay on top of it, and be a part of the solution. To give you an idea of trending articles, consider the how this past month saw questions and answers including:
As you will see, many of the new articles are focused on our SCIEX industry-leading software such as SCIEX OS and BioPharmaView. Make sure to visit the Knowledge Base to learn all the tips and trick so that you can get the max out of your software.
What is Premium Access Content?Now to the business of premium versus non-premium content. Premium Access Content is available to customers who own a mass spectrometer or CE instrument under warranty, or to anyone who has purchased a Software Support Plan. More specifically, the difference between premium and non-premium content is that premium content includes access to advanced workflows.
Knowledge Base Articles versus Community DiscussionsThe difference between the Knowledge Base Articles and Community Discussions is that Knowledge Base Articles come from the SCIEX support team and are based on common questions. If we see a trend in customer inquiries, the support team will create and post an article to help everyone out. Alternatively, the community is the ideal place to pose a question and get help from your peers. See a question that has yet to be answered?
As an analytical strategy, middle-down mass spectrometry (MS) workflows characterize biotherapeutic proteins by analyzing large, digested protein fragments or defined subunits, rather than fully intact proteins (top-down) or digested peptides (bottom-up). A middle-down strategy combines the strengths of top-down and bottom-up approaches by delivering high sequence coverage and structural specificity while maintaining relatively simple sample preparation. In practice, middle-down analysis enables accurate mass measurement, rapid sequence confirmation, and localization of key post-translational modifications (PTMs) on protein subunits that are directly relevant to product quality.
In biopharmaceutical development, sequence variants (SV) are considered an inherent risk of producing complex proteins in living systems. Sequence variants are unintended changes to the amino acid sequence of a biotherapeutic and can be caused by errors in transcription or translation in the host cell, or cell culture and process conditions. Detailed analysis of SVs is important in process and product development to ensure the drug’s safety and efficacy. Even low‑level sequence variants can have significant implications for product quality, safety, and efficacy, making their accurate detection and characterization a critical requirement across development, process optimization, and regulatory submission.
CE‑SDS remains a cornerstone assay for characterizing fragmentation, aggregation, and product‑related impurities in therapeutic proteins. UV detection has been the long‑standing standard. However, it frequently struggles with baseline noise, limited sensitivity for minor fragments, and subjective integration.
Posted by
You must be logged in to post a comment.
Share this post with your network